- Home
- BX vs TOVX Comparison
BX vs TOVX Comparison
Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BX
- TOVX
- Stock Information
- Founded
- BX 1985
- TOVX 2001
- Country
- BX United States
- TOVX United States
- Employees
- BX N/A
- TOVX N/A
- Industry
- BX Investment Managers
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BX Finance
- TOVX Health Care
- Exchange
- BX Nasdaq
- TOVX Nasdaq
- Market Cap
- BX 132.8B
- TOVX 4.5M
- IPO Year
- BX 2007
- TOVX 2006
- Fundamental
- Price
- BX $183.68
- TOVX $0.41
- Analyst Decision
- BX Buy
- TOVX Hold
- Analyst Count
- BX 17
- TOVX 1
- Target Price
- BX $167.88
- TOVX N/A
- AVG Volume (30 Days)
- BX 3.4M
- TOVX 372.5K
- Earning Date
- BX 10-16-2025
- TOVX 11-11-2025
- Dividend Yield
- BX 2.15%
- TOVX N/A
- EPS Growth
- BX 41.09
- TOVX N/A
- EPS
- BX 3.70
- TOVX N/A
- Revenue
- BX $13,505,742,000.00
- TOVX N/A
- Revenue This Year
- BX $1.25
- TOVX N/A
- Revenue Next Year
- BX $27.42
- TOVX N/A
- P/E Ratio
- BX $49.70
- TOVX N/A
- Revenue Growth
- BX 37.02
- TOVX N/A
- 52 Week Low
- BX $115.66
- TOVX $0.37
- 52 Week High
- BX $200.96
- TOVX $4.29
- Technical
- Relative Strength Index (RSI)
- BX 67.54
- TOVX 50.98
- Support Level
- BX $165.32
- TOVX N/A
- Resistance Level
- BX $186.65
- TOVX $0.45
- Average True Range (ATR)
- BX 3.72
- TOVX 0.02
- MACD
- BX 1.30
- TOVX -0.01
- Stochastic Oscillator
- BX 86.08
- TOVX 91.16
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.